NASDAQ — Healthcare: Manufacturing, Biotechnology: Laboratory Analytical Instruments
eyepointpharma.comIcon Bioscience Inc. and EyePoint Pharmaceuticals Inc. will complete a clinical trial evaluating the safety of DEXYCU, a short-term sustained release dexamethasone formulation, on February 1, 2026. This treatment is designed for anti-inflammatory therapy following cataract surgery, allowing for a single administration directly into the anterior chamber of the eye. The product is protected by patent US10028965, which is set to expire on May 23, 2034, highlighting its commercial value and importance in the ophthalmic market.
clinical trial completionEyePoint Pharmaceuticals, Inc. is conducting a Phase 3 clinical trial for EYP-1901, targeting the efficacy of the drug in treating wet age-related macular degeneration (wAMD). The trial is expected to conclude on August 1, 2027, and will assess EYP-1901 against Aflibercept. It is currently open for recruitment with an enrollment goal of 400 participants. The trial's results could significantly impact the treatment landscape for wAMD, a leading cause of vision loss. The clinical trial is registered under NCT06668064.
Clinical Trial CompletionPatent US8871241 relating to YUTIQ, an injectable drug delivery device by Eyepoint Pharmaceuticals Inc, is set to expire on August 12, 2027. The patent covers a device designed to deliver drugs over an extended period through a core containing drugs and polymers, which allows controlled release upon injection. The expiration may impact the competitive landscape for YUTIQ, enabling other companies to enter the market with similar or generic products, potentially affecting Eyepoint's revenue.
Patent ExpiryThe patent US8871241 for ILUVIEN, a drug delivery device developed by Eyepoint Pharmaceuticals Inc and Alimera Sciences Inc, is set to expire on August 12, 2027. This patent covers a unique injectable device that facilitates the controlled release of drugs through a polymer-based system, highlighting its relevance in drug formulation and delivery. The expiration of this patent may significantly affect the competitive landscape and market dynamics for ILUVIEN, allowing for potential generic alternatives that could impact revenue streams for both companies involved.
Patent ExpirationThe patent US7998108 related to YUTIQ, an intraocular drug delivery device developed by Eyepoint Pharmaceuticals Inc and Alimera Sciences Inc, is set to expire on January 12, 2028. This patent encompasses a device that includes an injector with various safety features designed for efficient handling and controlled penetration depth during injections. The expiration of this patent may allow for increased competition in the market for this type of drug delivery system, potentially impacting the financial performance of the companies involved as generic alternatives could emerge.
Patent ExpirationThe patent US10799642, associated with the DEXYCU KIT, is set to expire on May 11, 2032. This patent, attributed to Icon Bioscience Inc and EyePoint Pharmaceuticals Inc, covers devices that facilitate the loading and dispensing of precise small doses of fluid from standard injection syringes. The expiration could potentially impact the product's market exclusivity and open opportunities for generic alternatives, which may affect the financial landscape for both companies involved.
Patent EventPatent US10028965 for the DEXYCU KIT, developed by Icon Bioscience Inc and Eyepoint Pharmaceuticals Inc, is set to expire on May 23, 2034. The patent covers a short-term, sustained-release liquid formulation of dexamethasone, designed to provide anti-inflammatory therapy following cataract surgery through a single administration into the anterior chamber of the eye. This expiration could potentially allow for generic competition, impacting market exclusivity and associated revenues for the companies involved.
Patent ExpirationThe patent US10022502, assigned to Icon Bioscience Inc and EyetPoint Pharmaceuticals Inc, is set to expire on June 22, 2034, relating to the DEXYCU KIT. This patent covers devices that facilitate the accurate loading and dispensing of predefined doses of fluid from injection syringes, which is essential to the functionality of the DEXYCU KIT, a product designed for sustained release of a corticosteroid in the eye. The expiration may allow for increased competition in the market, impacting EyetPoint Pharmaceuticals' sales and market position.
Patent ExpirationPatent US11097061 for the DEXYCU KIT, developed by Icon Bioscience Inc and EyePoint Pharmaceuticals Inc, is set to expire on June 23, 2039. DEXYCU is a kit designed to facilitate the precise loading and delivery of small volume doses of medication, particularly at treatment sites, such as the conclusion of ocular surgeries. The expiration of this patent could potentially lead to increased competition in the market, as generics may emerge, impacting the financial landscape for the companies involved.
Patent